|
The event unit is anticipated to return.A follow-up report will be provided upon completion of investigation.In accordance with 21 cfr 803.56, if additional information is obtained, which was not known or was not available when this report was submitted, then a supplemental report will be submitted to the fda.There is no report of serious injury or death associated with this event.
|
|
Investigation summary: the event product was returned for evaluation along with two rubber fragments.The obturator and broken latch tab were not returned with the product.Engineering was able to confirm the customer's experience of seal fragmentation and latch tab separation.The two rubber fragments were reassembled, to form the septum, a part of the seal.The inner diameter of the septum was observed to be missing two small portions.Engineering attempted to replicate the customer's experience on the remaining latch tab on the returned product.Engineering was only successful after repetitively bending the latch tab before it broke off in a ductile manner, indicating no material abnormalities in the unit.During the manufacturing process, all trocars are thoroughly inspected for functionality and performance prior to packaging.The root cause of the septum fragmentation is likely due to damage caused by instruments used in the procedure.As stated in the instructions for use (ifu), "extra care should be used when inserting angular and asymmetrical instruments, such as 'j' hooks and clip appliers.All instruments should be centered axially when inserted through the seal to prevent tearing." although the exact root cause could not be confirmed, applied medical has opened a corrective and preventative action (capa) to further elevate and track this investigation and implement appropriate corrective actions to mitigate this type of event.The root cause of the latch tab breaking off is possibly due to improper handling.Although the root cause could not be confirmed, applied medical will continue to monitor its vigilance system for trends and take appropriate actions, as necessary, to ensure the performance and safety of its products.In accordance with 21 cfr 803.56, if additional information is obtained which was not known or was not available when this report was submitted, then a supplemental report will be submitted to the fda.
|